Anagrelide clinical trials
Also written SPD422.
How each study uses anagrelide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 14 Mar 1997 · AGRYLIN · NDA 020333 (FDA, Drugs@FDA)
- European Union
- 15 Nov 2004 · Xagrid · EMEA/H/C/000480 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2003 (2)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 2 |
| 2006 | 2 |
| 2010 | 2 |
| 2012 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Shire (6) · Mylan Pharmaceuticals Inc (2) · AOP Orphan Pharmaceuticals AG (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Anagrelide is the comparator. A study of two new drugs counts under both.
- 1Bomedemstat · Merck Sharp & Dohme LLC · next primary completion Jul 2027
- 1Ropeginterferon alfa-2b · PharmaEssentia
Studies
Open first, then newest update. How each study uses anagrelide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Fed Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mgCompletedPhase 1Mylan Pharmaceuticals IncNCT00648765Written as Anagrelide Hydrochloride Capsules 1 mg
- Fasting Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mgCompletedPhase 1Mylan Pharmaceuticals IncNCT00648024Written as Anagrelide Hydrochloride Capsules 1 mg
- The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET)CompletedPhase 2ShireNCT00413634Written as anagrelide hydrochloride
- Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (Anagrelide Hydrochloride) in Healthy Adult ParticipantsCompletedPhase 1ShireNCT03866434Written as SPD422
- Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential ThrombocythaemiaCompletedPhase 3ShireNCT01214915Written as Anagrelide Hydrochloride
- Long-term Safety of SPD422 in Japanese Adults With Essential ThrombocythaemiaCompletedPhase 3ShireNCT01467661Written as SPD422 (anagrelide hydrochloride)
- Effect of Anagrelide Hydrochloride on Any Changes in Heart Function in Healthy VolunteersCompletedPhase 1ShireNCT01552928Written as Anagrelide 0.5 mg
- A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia PatientsCompletedPhase 4ShireNCT00202644Written as Anagrelide
- Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential ThrombocythaemiaCompletedPhase 3AOP Orphan Pharmaceuticals AGNCT01065038Written as Anagrelide
As the comparator · 5 — what is tested is compared with anagrelide
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT06079879Written as Anagrelide
- Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or IntoleranceActive, not recruitingPhase 3PharmaEssentiaNCT04285086Written as Anagrelide
- Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)TerminatedPhase 2Incyte CorporationNCT03123588Written as Anagrelide
- The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second LineTerminatedPhase 2/3French Innovative Leukemia OrganisationNCT02962388Written as Anagrelide
- Anagrelide Retard in Essential ThrombocythemiaCompletedPhase 3AOP Orphan Pharmaceuticals AGNCT02076815Written as Thromboreductin
Codes
What other systems call anagrelide · ClinicalTrials.gg INT002738
- MeSH (NLM) C021139anagrelideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) K9X45X0051ANAGRELIDEConfirmed FDA, NLM, Wikidata
- RxNorm 596724Confirmed FDA, Wikidata
- Wikidata Q408163anagrelideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C28825AnagrelideOne source FDA
- DrugBank DB00261One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C021139 | anagrelide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | K9X45X0051 | ANAGRELIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 596724 | — | Confirmed FDA, Wikidata |
| Wikidata | Q408163 | anagrelide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C28825 | Anagrelide | One source FDA |
| DrugBank | DB00261 | — | One source Wikidata |
Also registered as anagrelide hydrochloride (UNII YTM763Y5C8) and anagrelide hydrochloride anhydrous (UNII VNS4435G39 · RxNorm 236612).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.